New data demonstrate benefits of cenobamate in uncontrolled epilepsy

Angelini Pharma, part of privately owned Italian drugmaker Angelini Industries, shared positive findings from clinical trials and real-world clinical practice in adults living with epilepsy and uncontrolled focal onset seizures.

The data demonstrated that treatment with cenobamate provided benefits beyond seizure reduction, leading to a decrease in hospitalizations and emergency department visits, alongside data demonstrating the potential to reduce SUDEP. These results were presented as part of the 36th International Epilepsy Conference (IEC) now taking place in Lisbon, Portugal.

Cenobamate is an anti-seizure medication (ASM) approved in Europe as adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications.1